Hyqvia Kit
Product Images NDC 0944-2512

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Hyqvia (NDC 0944-2512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Hyqvia 01)

An instructional illustration shows a hand placing a small vial labeled 'Hy' into a device connected to a larger vial labeled 'Ig'. A purple component is positioned nearby, suggesting a step in preparing or assembling the immune globulin infusion kit HYQVIA.*

FDA Label Image

Image (Hyqvia 02)

An instructional illustration showing a hand holding a HYQVIA kit vial labeled 'IG' and 'HA' while connecting it to a syringe. A downward red arrow indicates the direction to push or pull the syringe during the preparation process. This diagram visually demonstrates part of the medication preparation procedure for HYQVIA Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase.*

FDA Label Image

Image (Hyqvia 03)

An instructional illustration showing two methods to fill a syringe or infusion bag from a HYQVIA vial. The left side depicts a syringe being filled from an upside-down vial, while the right side shows the vial connected to an infusion bag for direct filling. Both illustrations include directional arrows indicating the flow of fluid.*

FDA Label Image

Image (Hyqvia 04)

Illustration showing a person applying a small adhesive patch or bandage to the abdominal area just above the beltline, suggesting a step in the administration or post-administration care related to HYQVIA immune globulin infusion kit use.*

FDA Label Image

Image (Hyqvia 05)

An anatomical illustration showing the front and back view of a human torso and hips. Four rectangular areas on the abdomen and hips are marked, likely indicating recommended infusion or injection sites for administration of a medication.*

FDA Label Image

Image (Hyqvia 06)

An instructional illustration showing a person holding an infusion device at a 90-degree angle to the skin on the abdomen. The image demonstrates the proper positioning for administering HYQVIA Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase.*

FDA Label Image

Image (Hyqvia 07)

An instructional illustration showing a person’s hands holding and using a syringe to administer an injection through the abdominal skin. The site is marked with a small adhesive patch, and tubing is connected to the injection area, suggesting infusion. The image demonstrates the technique for subcutaneous infusion likely related to administering immune globulin therapy.*

FDA Label Image

Figure 1 (Hyqvia 08)

A line graph depicting IgG concentration (g/L) over 28 study days comparing three treatments: IGIV 10%, Hyqvia, and IGSC 10%. The graph shows IgG levels on the vertical axis and study days on the horizontal axis, with dose adjustments indicated as 100%, 108%, and 137% respectively for each treatment.*

FDA Label Image

Image (Hyqvia 09)

An instructional diagram illustrating components of a medical infusion kit. It includes vials, a syringe, tubing, connectors, alcohol swabs, a sharps disposal container, a roll of tape, and other accessories typically used for intravenous or subcutaneous infusion procedures.*

FDA Label Image

Image (Hyqvia 10)

An instructional illustration depicting handwashing under running water from a faucet. The image shows both hands being washed, with water flowing over them. It is likely intended to demonstrate proper hygiene before handling the HYQVIA immune globulin infusion kit.*

FDA Label Image

Image (Hyqvia 11)

An instructional illustration showing hands holding a medical infusion kit containing two vials labeled 'Hy' and 'Ig.' This image demonstrates the preparation step for the HYQVIA Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase, kit by Takeda Pharmaceuticals America, Inc.*

FDA Label Image

Image (Hyqvia 12)

An instructional illustration showing a hand inserting a vial labeled 'Hy' into a clear medical device or kit, alongside another vial labeled 'Ig' and a purple accessory piece. The image relates to HYQVIA, an immune globulin infusion kit.*

FDA Label Image

Image (Hyqvia 13)

An instructional illustration showing a hand holding a vial labeled "Ig" and a syringe being inserted into the vial to draw liquid. This likely depicts preparation steps for the HYQVIA Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase kit by Takeda Pharmaceuticals America, Inc.*

FDA Label Image

Image (Hyqvia 14)

An instructional illustration showing a hand holding a syringe connected to tubing, with the other hand pressing a button or plunger on a device. A red arrow points to the area being pressed, suggesting activation or operation of the syringe device. The image likely relates to the use or preparation of a medication kit.*

FDA Label Image

Image (Hyqvia 15)

An instructional illustration showing two methods of drawing fluid from a bottle labeled with reverse text 'IG' and 'RH' into a syringe or into an infusion set bag. The image demonstrates proper handling of the HYQVIA immune globulin infusion kit components.*

FDA Label Image

Image (Hyqvia 16)

An instructional diagram showing the back of a human torso with two rectangular areas marked on the lower back. These areas likely indicate recommended infusion or injection sites for administration of the product HYQVIA, an Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase.*

FDA Label Image

Image (Hyqvia 17)

An instructional illustration showing a person administering a subcutaneous injection or infusion in the abdominal area using a small adhesive patch or device. The image highlights hand placement and the site of application near the navel.*

FDA Label Image

Image (Hyqvia 18)

An instructional illustration showing the administration of an injection at a 90-degree angle to the skin on the abdomen. It depicts a hand holding a syringe or infusion set, guiding the needle insertion into the skin, likely demonstrating proper use technique for HYQVIA immune globulin infusion kit.*

FDA Label Image

Image (Hyqvia 19)

An instructional illustration showing a hand holding a syringe and attaching it to an infusion set placed on a patient's abdomen. The image depicts the process of connecting a syringe to deliver HYQVIA, an immune globulin infusion, for subcutaneous administration.*

FDA Label Image

Image (Hyqvia 20)

An instructional illustration showing a person attaching or adjusting an infusion set on their abdomen. The image focuses on the hand connecting a small device or needle to the skin, indicating a step in the infusion process likely related to subcutaneous administration.*

FDA Label Image

Principal Display Panel (2.5 g/25 mL Vial Label)

Label of HYQVIA Immune Globulin Infusion 10% (Human) showing a single-use vial component with 2.5 g / 25 mL concentration. The label includes instructions for infusion order ("Infuse 2nd"), manufacturer information as Baxalta US Inc. (a Shire company), and regulatory details such as lot and expiration placeholders. The label also highlights that the product is Rx only.*

FDA Label Image

Principal Display Panel (1.25 mL Vial Label)

Label of a single-use vial of Recombinant Human Hyaluronidase, a component of HYQVIA, indicating 1.25 mL volume with 160 units per mL. The label includes directions to infuse first and product origin from Baxter Healthcare Corporation, Deerfield, IL, USA, with Shire branding. Lot/expiry date area and barcode are also visible.*

FDA Label Image

Principal Display Panel (2.5 g/25 mL Kit Carton)

HYQVIA Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase, 2.5 g/25 mL kit packaging label from Takeda Pharmaceuticals America, Inc. The label includes dosing details, storage instructions, and manufacturer information. The product is for subcutaneous administration only and comes as a single-use dual vial unit without preservatives. The label features purple, orange, and green design elements with barcodes and legal notices.*

FDA Label Image

Principal Display Panel (5 g/50 mL Vial Label)

Label of a single-use vial of Immune Globulin Infusion 10% (Human), 5 g/50 mL, component of HYQVIA. The label includes usage instructions to infuse second, manufacturer details (Baxalta US Inc., Lexington, MA), and barcode. The label also shows the NDC and Lot/expiration date fields, labeled under HYQVIA by Takeda Pharmaceuticals America, Inc.*

FDA Label Image

Principal Display Panel (2.5 mL Vial Label)

Packaging label for a single-use vial of Recombinant Human Hyaluronidase, a component of HYQVIA. The vial contains 2.5 mL with 160 units per mL concentration. Label indicates 'Infuse 1st' and is labeled for prescription use only (Rx Only). Manufactured by Baxter Healthcare Corporation, Deerfield, IL, USA, under the Shire brand.*

FDA Label Image

Principal Display Panel (5 g/50 mL Kit Carton)

HYQVIA Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase 5 g/50 mL kit packaging. The label includes directions for subcutaneous administration, notes the product is preservative-free and single-use, and indicates it is manufactured by Takeda Pharmaceuticals America, Inc., formerly Shire and Baxalta US Inc. The carton provides storage instructions and patent information, featuring purple and orange design elements.*

FDA Label Image

Principal Display Panel (10 g/100 mL Vial Label)

HYQVIA Immune Globulin Infusion 10% (Human) component vial label showing strength as 10 g/100 mL IG. The label indicates it is a single-use vial, Rx only, manufactured by Baxalta US Inc., Lexington, MA, with a barcode and lot/expiry date sections. The Shire logo is visible along with NDC 0944-2717-10.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Label for Recombinant Human Hyaluronidase, a component of HYQVIA, in a single-use 5 mL vial with 160 units per mL concentration. The label indicates 'Infuse 1st' and is marked Rx Only. It is manufactured by Baxter Healthcare Corporation, Deerfield, IL, with branding from Shire.*

FDA Label Image

Principal Display Panel (10 g/100 mL Kit Carton)

HYQVIA Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase kit packaging label. The label shows the active ingredient concentration as 10 g per 100 mL and identifies the product for subcutaneous administration only. The kit contains a single-use dual vial unit and includes storage instructions, manufacturer details (Baxalta US Inc., Lexington, MA), and customer service information. The label features purple and orange design elements and the Shire logo.*

FDA Label Image

Principal Display Panel (20 g/200 mL Vial Label)

Label for Immune Globulin Infusion 10% (Human), a component of HYQVIA. The label indicates a single-use vial of 20 g/200 mL Ig infusion. It shows manufacturer details as Baxalta US Inc., Lexington, MA. The label includes batch information, barcode, and the Shire logo, with dosage instruction "Infuse 2nd."*

FDA Label Image

Principal Display Panel (10 mL Vial Label)

Packaging label for Recombinant Human Hyaluronidase, a component of HYQVIA. The label indicates it is a single-use vial, marked Rx Only, manufactured by Baxter Healthcare Corporation. The vial contains 10 mL with 160 units per mL, showing a red emblem with 'HY' and includes a barcode and Shire branding.*

FDA Label Image

Principal Display Panel (20 g/200 mL Kit Carton)

HYQVIA Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase 20 g/200 mL kit packaging label. The label shows product details including dosage form as a kit, manufacturer Baxalta US Inc., and instructions for subcutaneous administration only. The label also includes storage instructions, contents, and trademark information. The design features purple and orange accents with the Shire logo.*

FDA Label Image

Principal Display Panel (30 g/300 mL Vial Label)

Label for Immune Globulin Infusion 10% (Human), component of HYQVIA, single-use vial. The label shows a 30 g/300 mL concentration with an IG designation, and includes text indicating 'Infuse 2nd' along with manufacturer information listing Baxalta US Inc. The label also displays NDC 0944-2719-30 and Shire and LE-07-40442 logos.*

FDA Label Image

Principal Display Panel (15 mL Vial Label)

Label for Recombinant Human Hyaluronidase, a component of HYQVIA kit. The label indicates it is a single-use vial for infusion first, with 15 mL containing 160 units per mL. It is Rx only and labeled by Baxter Healthcare Corporation, Deerfield, IL. The Shire logo also appears on the label.*

FDA Label Image

Principal Display Panel (30 g/300 mL Kit Carton)

HYQVIA Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase 30 g per 300 mL kit packaging label. The product is for subcutaneous administration only, Rx only, and distributed by Takeda Pharmaceuticals America, Inc. The carton includes storage instructions, product contents, and manufacturer information, with branding by Shire and BAXALTA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.